The fentanyl crisis has reached devastating levels, taking lives at an alarming rate. As one of the most potent synthetic opioids, fentanyl is often mixed with other drugs, making unintentional exposure a deadly risk. Recognizing the urgency of this crisis, EKLA Corp is proud to announce the launch of its Fentanyl Rapid Urine Test, a critical tool in harm reduction and public safety.
A Personal Mission for Erin Lu, EKLA’s President
For EKLA President Erin Lu, bringing this test to market was more than just business—it was a mission. Witnessing the fentanyl epidemic’s impact on families, first responders, and communities across North America, Erin saw the desperate need for a rapid, accurate, and easy-to-use test that could detect fentanyl before exposure occurs. The current reliance on fentanyl test strips presents limitations, requiring sample dilution and often leading to false negatives.
EKLA’s Fentanyl Rapid Test eliminates these barriers by providing:
✅ More accurate detection – Identifies fentanyl and key analogs with high sensitivity.
✅ Faster results – Delivers answers within minutes.
✅ No dilution required – Reduces user error and simplifies the process.
✅ Easy-to-read format – Ensures clear results for healthcare professionals and individuals alike.
✅ Enhanced safety – Helps prevent accidental overdoses by allowing users to make informed decisions.
Now Available on Vizient Contract LB0812
EKLA’s Fentanyl Rapid Test is now listed on Vizient contract LB0812, making it widely accessible to hospitals, emergency departments, harm reduction programs, and other healthcare organizations. As one of the leading group purchasing organizations in the U.S., Vizient’s contract allows institutions to streamline procurement and ensure they have the best tools available to combat the opioid epidemic.
A Commitment to Public Health and Safety
At EKLA, we believe that innovation can save lives. Our Fentanyl Rapid Test is designed to empower individuals, healthcare professionals, and community programs with a reliable and easy-to-use solution for detecting fentanyl contamination. As the opioid crisis continues to evolve, EKLA remains committed to providing cutting-edge diagnostic solutions that address real-world challenges.
This launch is just the beginning. EKLA will continue to expand its Rapid Diagnostic Test Kits portfolio, ensuring that healthcare providers and at-risk populations have access to the tools they need to stay safe.
🔗 Learn more about EKLA’s Fentanyl Rapid Test here: https://www.eklacorp.com/rapidtests
Commentaires